Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)

* STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive cases * Findings support the potential value of a comprehensive testing approach that provides both HPV and STI pathogen information * Seegene to v...

2026-07-27 21:00 8308

Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)

Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

TAIPEI, July 27, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics,today reaffirmed its strategic focus on pursuing global li...

2026-07-27 20:20 5455

Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer

* Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. * Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volum...

2026-07-27 20:10 5766

Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer

Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors CAMBRIDGE, Mass...

2026-07-27 20:00 8503

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

CHENGDU, China, July 27, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)...

2026-07-27 19:40 6134

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug Administration (FDA...

2026-07-27 18:42 6553

Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential

BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over time Fast-onset and potent itch relief was observed as early as Day 1 after the first dose alongside robust and durable suppression of Ty...

2026-07-27 18:00 5639

Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has ent...

2026-07-27 17:02 5666

Jiangxi Bio's Veterinary Tetanus Antitoxin Production Line Officially Commenced Production,Accelerating Commercialization of the Animal Antiserum Portfolio

HONG KONG, July 27, 2026 /PRNewswire/ -- Jiangxi Institute of Biological Products Inc. and its subsidiaries (collectively, "Jiangxi Bio" or the "Group") (stock code: 6915.HK) is pleased to announce that the veterinary tetanus antitoxin ("Veterinary TAT") production line of Chifeng Bo-en Pharmaceu...

2026-07-27 15:36 7839

Jiangxi Bio's Veterinary Tetanus Antitoxin Production Line Officially Commenced Production,Accelerating Commercialization of the Animal Antiserum Portfolio

IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation

Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...

2026-07-27 11:00 2201

Seaweed extract shown to relieve prostate symptoms

In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH). HOBART, Australia, July 27, 2026 /PRNewswire/ -- A randomised, double-blind, placebo-controlled clinical...

2026-07-27 07:00 1816

Seaweed extract shown to relieve prostate symptoms

Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of i...

2026-07-24 09:30 2449

ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clini...

2026-07-24 09:00 3144

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a ...

2026-07-24 08:02 7231

AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This m...

2026-07-23 22:00 2682

Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH

BEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has receivedmarketing approval from the National Medical Products Administration of China (NMPA) for t...

2026-07-23 14:08 2055

Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH

Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases

Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice ® transgenic mouse technology platform for translational antibody research CAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and de...

2026-07-23 08:55 3305

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting

- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ...

2026-07-23 08:10 4161

Samsung Biologics Reports Second Quarter 2026 Financial Results

* Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion * Delivered stable business performance through continued disciplined execution * Expanded global presence while advancing innovation and future growth initiatives INCHEON, South Korea, July 23, 2026 /PRNe...

2026-07-23 07:03 4582

Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management

* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class,brain -penetrant, non-opioid solution for pain management. * Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated super...

2026-07-22 21:00 5009

1 ... 24 25 262728 29 30 ... 351